Search
Dipivefrin
go.drugbank.com/drugs/DB00449ApprovedWithdrawnDipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
Iodipamide
go.drugbank.com/drugs/DB04711ApprovedWithdrawnIodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Aluminum chloride
go.drugbank.com/drugs/DB11081ApprovedInvestigationalAluminum chloride is a chemical compound with the chemical formula AlCl3. When contaminated with iron chloride, it often displays a yellow color compared to the white pure compound. It is used in various chemical applications as a Lewis ...
Indopan
go.drugbank.com/drugs/DB01446ExperimentalIllicitIt was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.
Col-118
go.drugbank.com/drugs/DB05778InvestigationalIt is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.
CLX-0921
go.drugbank.com/drugs/DB05854ExperimentalIt is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.
BW-A 58C
go.drugbank.com/drugs/DB06740Experimentalnaphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by
Taspoglutide
go.drugbank.com/drugs/DB14027InvestigationalTaspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.
AZD7442
go.drugbank.com/drugs/DB15787Investigational[L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]